Cargando…

Epstein-Barr virus as a marker of biological aggressiveness in breast cancer

PURPOSE: Although a potential role of the Epstein-Barr virus (EBV) in the pathogenesis of breast cancer (BC) has been underlined, results remain conflicting. Particularly, the impact of EBV infection on biological markers of BC has received little investigation. METHODS: In this study, we establishe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazouni, C, Fina, F, Romain, S, Ouafik, L, Bonnier, P, Brandone, J-M, Martin, P-M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031896/ https://www.ncbi.nlm.nih.gov/pubmed/21179039 http://dx.doi.org/10.1038/sj.bjc.6606048

Ejemplares similares

Reply: Is Epstein–Barr virus associated with aggressive forms of breast cancer?
por: Mazouni, C, et al.
Publicado: (2011)

Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma
por: Ji, M F, et al.
Publicado: (2007)

Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas
por: Fina, F, et al.
Publicado: (2001)

A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein–Barr virus in adults with human immunodeficiency virus-1
por: Newton, R, et al.
Publicado: (2006)

Epstein-Barr Virus latent membrane protein 1 induces Snail and epithelial–mesenchymal transition in metastatic nasopharyngeal carcinoma
por: Horikawa, T, et al.
Publicado: (2011)

Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer
por: Wong, H, et al.
Publicado: (2010)

Osteopontin is a marker for cancer aggressiveness and patient survival
por: Weber, G F, et al.
Publicado: (2010)

Is Epstein–Barr virus associated with aggressive forms of breast cancer?
por: Khan, G, et al.
Publicado: (2011)

Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer
por: Nalwoga, H, et al.
Publicado: (2010)

The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
por: Ragnum, H B, et al.
Publicado: (2015)

c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays
por: Garcia, S, et al.
Publicado: (2007)

Epstein-Barr Virus and Neurological Diseases
por: Zhang, Nan, et al.
Publicado: (2022)

Absence of the DNA repair enzyme human 8-oxoguanine glycosylase is associated with an aggressive breast cancer phenotype
por: Karihtala, P, et al.
Publicado: (2012)

Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis
por: Cao, R, et al.
Publicado: (2014)

Lack of correlation of stem cell markers in breast cancer stem cells
por: Liu, Y, et al.
Publicado: (2014)

Nuclear osteopontin-c is a prognostic breast cancer marker
por: Zduniak, K, et al.
Publicado: (2015)

Low ANXA10 expression is associated with disease aggressiveness in bladder cancer
por: Munksgaard, P P, et al.
Publicado: (2011)

FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer
por: Baker, M J, et al.
Publicado: (2008)

miR-30e* is an independent subtype-specific prognostic marker in breast cancer
por: D'Aiuto, F, et al.
Publicado: (2015)

Testosterone regulates cell proliferation in aggressive fibromatosis (desmoid tumour)
por: Hong, H, et al.
Publicado: (2011)

Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction
por: Baneshi, M R, et al.
Publicado: (2010)

Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer
por: Talvinen, K, et al.
Publicado: (2008)

Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastases
por: Dzieȩgiel, P, et al.
Publicado: (2010)

Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer
por: Ali, A M G, et al.
Publicado: (2011)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error
por: Shipitsin, M, et al.
Publicado: (2014)

Validation of UBE2C protein as a prognostic marker in node-positive breast cancer
por: Loussouarn, D, et al.
Publicado: (2009)

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer
por: Ali, H R, et al.
Publicado: (2012)

The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer
por: Beresford, M J, et al.
Publicado: (2006)

Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome
por: Fangusaro, J R, et al.
Publicado: (2005)

Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response
por: Thoms, J W, et al.
Publicado: (2012)

Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness
por: Weiswald, L-B, et al.
Publicado: (2009)

FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer
por: Cimino, Y, et al.
Publicado: (2012)

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis
por: Walsh, N, et al.
Publicado: (2010)

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers
por: Sung, Hyuna, et al.
Publicado: (2016)

Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation
por: Chugh, Seema, et al.
Publicado: (2016)

Separase is a marker for prognosis and mitotic activity in breast cancer
por: Gurvits, Natalia, et al.
Publicado: (2017)

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype
por: Ameri, K, et al.
Publicado: (2010)

A putative OTU domain-containing protein 1 deubiquitinating enzyme is differentially expressed in thyroid cancer and identifies less-aggressive tumours
por: Carneiro, A P, et al.
Publicado: (2014)

Epstein–Barr virus gene expression in human breast cancer: protagonist or passenger?
por: Xue, S A, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_hirvcn9nfh36m9dkqrvafuvd2d